Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
- Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
- Indication
Teriparatide is indicated:
- Associated Conditions
- Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
- Associated Therapies
- -
Cyclic Versus Daily Teriparatide on Bone Mass
- Conditions
- Interventions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Helen Hayes Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT00668941
- Locations
- 🇺🇸
Helen Hayes Hospital, West Haverstraw, New York, United States
Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD
- Conditions
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2008-03-13
- Lead Sponsor
- Nastech Pharmaceutical Company, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT00624481
Use of Teriparatide to Accelerate Fracture Healing
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 10
- Registration Number
- NCT00594906
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy
- Conditions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2009-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00577863
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beckley, West Virginia, United States
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2011-11-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT00557310
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada
Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Radius Health, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT00542425
- Locations
- 🇺🇸
Radius Health, Inc., Cambridge, Massachusetts, United States
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- TransPharma Medical
- Target Recruit Count
- 104
- Registration Number
- NCT00535860
- Locations
- 🇨🇿
Osteocentrum 3 .Interni Klinika 1. LFUK a VFN, Prague, Czech Republic
🇮🇱Hillel Yafe Medical Center - Endocrinology dep, Hadera, Israel
🇨🇿Osteocentrum FN, Hradec Kralove, Czech Republic
Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00532207
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation
Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT00532545
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 92
- Registration Number
- NCT00503399
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.